Prognostic factors and outcome of <scp>E</scp>pstein–<scp>B</scp>arr virus <scp>DNA</scp>emia in high‐risk recipients of allogeneic stem cell transplantation treated with preemptive rituximab

Abstract

We conclude that CD4+ cell count at day +30 is a predictive factor for EBV DNAemia and may help identify patients requiring closer monitoring. Although only 3% of patients progressed to PTLD and were all successfully managed, EBV reactivation was associated with higher TRM, mainly because of infections.